



The 9th ISMI-HOTTI 2024

The International Scientific Meeting on Hematology, Oncology, Thrombosis, Transplantation & Transfusion in Indonesia

with the HIGHLIGHTS

1. The First (1st) ISHMO & ASCO JOINT SESSION (The Indonesian Society of Hematology & Medical Oncology and The American Society of Clinical Oncology) (a replacement of the BEST of ASCO 2022 and the BEST of ASCO 2023)
2. The First (1st) ESMO PAGA IMPLEMENTATION in Indonesia (The European Society of Medical Oncology Pan-Asian Guidelines Adaptation)
3. The First (1st) ISHMO and NCCN COMMUNICATION (The National Comprehensive Cancer Network)
4. The First (1st) INAGHMO NETWORK (The Indonesian National Guidelines on Hematology and Medical Oncology) in CONJUNCTION with:
 5. The Fourteenth (14th) SEAMOF (The Southeast Asia Medical Oncology Network Forum)
 6. The First (1st) SEAMOF and EAMO NETWORK (The Southeast Indonesia Medical Oncology Network Forum and The East Asia Medical Oncology Network)
 7. The Sixth (6th) SEAHEF (The Southeast Asian Hematology Network Forum)
 8. The Fourth SEATHAF (The Southeast Asia Thalassemia Network Forum) PANEL DISCUSSION
 9. The AFH (The ASEAN Federation of Hematology) PANEL DISCUSSION to DISCUSS the FUTURE
10. The Eleventh (11th) JAMHEMOP (Jakarta Megapolitan Hematology Oncology Forum): Summer Camp Basic HOME (July, August) & Winter Game Basic HOME (December, January)
11. The First (1st) PERHOMPEDIN, PDSPA, PDSRI, PERDAFKI, HISFARSI, HIMPONI & BPJSK Network Forum in Systemic & Supportive Therapy in Solid Tumor Cancer
12. The First (1st) PHTDI and BPJSK Network Forum in Hemophilia, Thalassemia, Leukemia, Multiple Myeloma, Lymphomas, and Bone Marrow Transplant
13. The First (1st) Inauguration of the Centers and Units of Systemic and Supportive Therapy in Cancer Patients throughout Indonesia
14. The First (1st) CHMO & IFO Alumni Networking (Consultant of Hematology & Medical Oncology, Internist Fellow Oncology), Dr Cipto Mangunkusumo Hospital: Healthy Our Hometown (HOH) Program: "JAKARTA SEHAT"
15. The First (1st) DOARI HOME Alumni Networking (Dokter Asisten Riset Indonesia Hematologi & Onkologi Medik), Dr Cipto Mangunkusumo Hospital



Jakarta, Ritz-Carlton Mega Kuningan Hotel, Friday 28th until Sunday 30th of June, 2024

A. FRIDAY, JUNE 28th, 2024 (DAY 1)



TIME	FRIDAY, June 28 th , 2024	
	BALL ROOM 1	BALL ROOM 2
07.00 – 08.00	RESIDENCE of INTERMIST SELF ASSESSEMNET (RISA): SERIAL 1 of HEMATOLOGY (June 2024) organized by JAMHEMOF (Jakarta Megapolitan Hematology & Medical Oncology Forum) for Residents of Internal Medicines	RESIDENCE of INTERNIST SELF ASSESSEMNET (RISA): SERIAL 2 of MEDICAL ONCOLOGY (June 2024) organized by JAMHEMOF (Jakarta Megapolitan Hematology & Medical Oncology Forum) for Residents of Internal Medicines
	INTERACTIVE CASE DISCUSSION with Polling System in HEMATOLOGY: CHEMOTHERAPY INDUCED NAUSEA VOMITING (CINV) and HEMOGLOBINOPATHY (THALASSEMIAS & HEMOGLOBIN STRUCTURAL VARIANTS)	INTERACTIVE CASE DISCUSSION with Polling System in MEDICAL ONCOLOGY: CANCER PAIN and MYELOPROLIFERATIVE NEOPLASM (MPN)
08.00 – 10.50	JAMHEMOF -EDUCATION PROGRM, HEALTHY JAKARTA SUMMER CAMP BASIC HOME (HETERO) TUTORIAL 1: CHEMOTHERAPY INDUCED NAUSEA & VOMITING (CINV): What is the Best Antiemetic Combination in preventing CINV	JAMHEMOF-EDUCATION PROGRAM: HEALTHY JAKARTA SUMMER CAMP BASIC HOME (BETA FARMA MAHAKAM) TUTORIAL 2: CANCER PAIN: From the BASIC KNOWLEDGE to the CANCER PAIN MANAGEMENT (for Subspecialists, Specialists, GPs)
08.00 – 09.00	SESSION 1: Moderator: Ary Harryanto Reksodiputro, Prof, PhD, Internist, Consultant Hematology & Medical Oncology (Jakarta)	SESSION 1. CANCER PAIN BASIC PRINCIPLES
08.00 – 08.20	1.CINV: Introduction, Definition, Types / Classification, Pathophysiology (including, 5HT3, NK1 Receptors, etc), Pathopsychology (Demographic & Treatment Related Factors), WHO Doddy Ranuhardy, PhD, Internist, consultant Hematology & Medical Oncology (Jakarta)	1.CANCER PAIN: Introduction, Pathogenesis, Classification, Assessment, Types / Pattern, Brief Pain Inventory (BPI) Findy Prasetyawati, Internist, Consultant Hematology & Medical Oncology (Jakarta)
08.20 – 08.40	2. ANTIEMESIS for CINV: 5-HT3 inhibitors/ receptor antagonist (RA), NK1 RA, Neuroleptic Drugs, Dexamethasone and other drugs, Principles Emesis Control for Patients with Cancer, Toxicity grading systems (WHO scoring system & Common Toxicity Criteria Tubagus Djumhana Atmakusuma, PhD, Consultant Hematology & Medical Oncology (Jakarta)	2. MANAGING CANCER PAIN: Analgesic Classification, Pain pathway and multi-modal mechanism of pain treatment, WHO Step Ladder, Pain treatment based on severity and presence of inflammation, Advantages & Disadvantages of Paracetamol, NSAID/COX-2 inhibitors,) Rahmat Cahyanur, Internist, Hematology & Medical Oncology (Jakarta)
08.40 – 09.00	3. INTERACTIVE CASE DISCUSSION with POLLING SYSTEM	3. INTERACTIVE DISCUSSION with POLLING SYSTEM
09.00 – 10.00	SESSION 2: Moderator: Nuzirwan Acang, Prof, Internist, Consultant Hematology & Medical Oncology (Jakarta)	SESSION 2. CANCER PAIN MANAGEMENT
09.00 – 09.20	1. EMETOGENIC POTENTIAL OF PARENTERAL & ORAL ANTICANCER AGENTS: a. Minimal, Low Emetic, Moderate to High Emetic Risk of antineoplastic agents	1. OPIOID OPTIONS: Profile of opioid analgesics, Oral and parenteral opioid equivalences and relative potency of drugs, Opioid rotation (Switching, Recommended dose conversion from other opioid to transdermal Fentanyl, How to start with opioids? Initiating short acting opioids in opioid naive

	b. Acute and delated emesis prevention of CINV Faisal Driza Hasibuan, Inernistt, Consultant Hematology Oncology (Jakarta)	patients, Management of pain in opioid tolerant patients, Managing severe pain in cancer patient, Cessation of therapy Asrul Harsal, Interist, Consultant Hematology & Medical Oncology (Jakarta)
09.20 – 09.40	2. Algorithm of the use of anti-emetic agents in CINV, Breakthrough treatment of CINV Amaylia Oehadian, PhD, Internist, Consultant Hematology Oncology (Jakarta)	2. OPIOID SIDE EFFECTS: Opioid related side effects, Principles to minimize the side effects of opioid, Definition of drug abuse/addiction, Physical dependence, Tolerance, Differences between a pain patient and addicted patient Noorwati Sutandyo, Prof, PhD, Internist Consultant Hematology& Medical Oncology (Jakarta)
09.40 – 10.00	3. INTERACTIVE CASE DISCUSIION with POLLING SYSTEM	3. INTERACTIVE CASE DISCUSIION with POLLING SYSTEM
10.00 – 11.00	The 4th SOUTHEAST ASIAN THALASSEMIA FORUM (SEATHAF) TUTORIAL 3: HEMOGLOBINOPATHY: From the BASIC KNOWLEDGE to the GENETIC COUNSELING in (for Subspecialists, Specialists, GPs, Nurses & Midwives)	JAMHEMOF-EDUCATION PROGRAM: HEALTHY JAKARTA SUMMER CAMP BASIC HOME (NOVARTIS) TUTORIAL 4. MYELOPROLIVERATIVE NEOPLASM (MPN): From BASIC KNOWLEDGE to the CLINICAL MANAGEMENT of POLYCYTHEMIA VERA (PV) & PRIMARY MYELOFIBROSIS (PMF) (for Subspecialists, Specialists, General Practitioner /GPs), Nurses, Parents & Patients
10.00 – 11.00	SESSION 1: Moderator: Agus Kosasih, PhD, Clinical Pathologist, Consultant Hematology (Jakarta)	SESSION 1. PRIMARY MYELOFIBROSIS (PMF)
10.00 – 10.20	1. HEMOGLOBINOPATHY (THALASSEMIA Alpha & Beta, and HEMOGLOBIN STRUCTURAL VARIANTS): BASIC PRINCIPLES Iswari Setyaningsih, PhD, Pediatrician (Jakarta)	1. PMF: Update 2017 update on diagnosis, risk-stratification, and management. Darwin Prenggono, PhD, Internist, Consultant of Hematology & Medical Oncology (Banjarmasin)
10.20 – 10.40	2. Diagnosis of Hemoglobinopathy: CBC, Red cell indices, Morphology, Hemoglobin Analysis (Advantages of Capillary Electrophoresis compared to HPLC) Ninik Sukartini, PhD, Clinical Pathologist, Consultant Hematology (Jakarta)	2. MPN: Pathological, molecular pattern and the role as well as correlation with Ruxolitinib Tubagus Djumhana Atnakusuma, PhD, Internist, Hematology& Medical Oncology (Jakarta)
10.40 – 11.00	3. INTERACTIVE CASE DISCUSIION with POLLING SYSTEM	3. INTERACTIVE CASE DISCUSIION with POLLING SYSTEM
11.00 – 11.20	SESSION 2: Moderator: Teny Tjitra Sari, PhD, Pediatrician, Consultant Hematology Oncology)	SESSION 2. POLYCYTHEMIA VERA (PV)
11.20 – 11.40	1. Thalassemia in Children & Adolescent: Genotypes & Phenotypes, Complications, Monitoring and Preventions Pustika Amalia, Prof, Pediatrician, Hematology Oncology (Jakarta)	1. PV: Clinical Manifestation, 2017 WHO PV DIAGNOSIS CRITERIA, Treatment of Choices, Complication Prevention and Treatment Lugyanti Sukrisman, PhD, Internist, Consultant Hematology & Medical Oncology (Jakarta)
11.40 – 12.00	2. Thalassemia in Adults: Genotypes & Phenotypes, Complications, Monitoring and Preventions:	2. When and How is RUXOLITINIB (JAKAVI) Used in Patients with PV? What should Special Precautions be Followed?

	Tubagus Djumhana Atmakusuma, PhD, Internist, Consultant Hematology & Medical Oncology (Jakarta)	Nadia Ayumulansari , Internist, Consultant Hematology & Medical Oncology (Jakarta)
	3. INTERACTIVE CASE DISCUSSION with POLLING SYSTEM	3. INTERACTIVE CASE DISCUSSION with POLLING SYSTEM
12.00 – 12.45	FRIDAY PRAYER, LUNCH TIME & POSTER SESSION	
	BALL ROOM 1	BALL ROOM 2
12.45 – 17.00	The 4th SOUTHEAST ASIAN THALASSEMIA FORUM (SEATHAF)	The First (1st) ESMO PAGA IMPLEMENTATION in INDONESIA
12.45– 13.00	INTRODUCTION: Southeast Asia Thalassemia Forum (SEATHAF) from 2017 to 2024m after 7 years: What have we had? and What we should do in the future? Opening Speech from SEAHEF Opening Speech from SEATHAF	INTRODUCTION: ESMO PAGA (The European Society of Medical Oncology Pan-Asian Guidelines Adaptation) Opening Speech from ESMO ASIA Opening Speech from ISHMO
13.00 – 13.30	CORPORATE SYMPOSIUM 1 (HYBRIBIO / T BESTARI SUKSES MAKMUR) Moderator 1: Tubagus Djumhana Atmakusuma, PhD, Internist Consultant Hematology& Medical Oncology (Jakarta) Moderator 2: Anna Mira Lubis, Internist Consultant Hematology& Medical Oncology (Jakarta) 1.Molecular Diagnostic of Hemoglobinopathy (Thalassemia and Hemoglobin Structural Variants) using GENOME ARRAY Method	ESMO PAGA 1: BILIARY TRACT CANCER 1.IMPLEMENTATION of ESMO PAGA Guideline of Biliary Tract Cancer (15') Presenter: Eko Adhi Pangarsa, PhD, Internist, Consultant Hematology & Medical Oncology (Semarang) 2. Case Interactive Discussion (15') - Resource: Wifanto Saditya Jeo, Surgeon, Consultant Digestive Surgery (Jakarta)
13.30 – 14.00	Benjamin Tong, MSc (HYBRIBIO Hong Kong) 2. Molecular Diagnostic of Hemoglobinopathy (Thalassemia and Hemoglobin Structural Variants) in Prenatal Diagnosis using GENOME ARRAY Method Joane, PhD (HYBRIBIO, Chaozhou, Guangdong, China) 3. Panel Discussion: Panelists: Suthat Fuchroen, Prof Chen Ping, Prof	ESMO PAGA 2: ENDOMETRIAL CANCER 1.IMPLEMENTATION of ESMO PAGA Guideline of Endometrial Cancer (15') Presenter: Wulyo Rajabto, Internist, Consultant Hematology & Medical Oncology (Jakarta) 2. Case Interactive Discussion (15') -Resource: Tricia Dewi Anggraeni, Obstetric Gynecologist, Consultant Oncology (Jakarta)
14.00 – 14.30	TUTORIAL 5. THALASSEMIA SCREENING PROGRAM (A) ANTENATAL SCREENING/INVASIVE PRENATAL DIAGNOSIS and PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) (the Indonesian Society of Hematology & Transfusion Medicine / ISHTM/ PHTDI & the Indonesian Society of Obstetric Gynecology Association/POGI Joint Session including the Indonesian Midwife Association	ESMO PAGA 3: NON-SMALL CELL LUNG CANCER (NSCLC) 1.IMPLEMENTATION of ESMO PAGA Guideline of NSCLC (15') Presenter: Sri Agustini Kurniawati, Internist, Consultant Hematology & Medical Oncology (Jakarta) 2. Case Interactive Discussion (15') -Resource: Mira Yulianti, Internist, Consultant Respirology & Intensive Care (Jakarta)
14.30 – 15.00	Moderator: Didi Danukusumo, PhD, Obstetrics & Gynecology Consultant Fetomaternal (Jakarta) 1.Antenatal Screening / Invasive Prenatal Diagnosis using Villi Chorialis of the Placenta, Amnion fluid and Umbilical Blood: When and how do you do these methods?	ESMO PAGA 4: NASOPHARYNGEAL CANCER (NPC)1. 1. IMPLEMENTATION of ESMO PAGA Guideline of NPC (15') Presenter: Johan Kurnianda, Internist, Consultant Hematology & Medical Oncology (Yogyakarta) 2. Case Interactive Discussion: ? (15')

	<p>R Aditya Kusuma, PhD, MSc, Obstetrics Gynecology</p> <p>2. Pre implantation Genetic Diagnosis (PGD): How and when do you do this procedure? Does it work well? Is there any objection from MUI ?</p> <p>Hadi Sjarbaini, Obstetric Gynecology, F.IND-INF</p> <p>3. Panel Discussion:</p> <ul style="list-style-type: none"> - Sri Sulistyowati, Prof, PhD, Obstetrics Gynaecology, Consultant Fetomaternal (Solo) - Wiryawan Permadi, Prof, PhD, Obstetric Gynaecology, Consultant Fertility-Endocrinology -Reproduction (Bandung) - Joane, PhD (HYBRIBIO, Chaozhou, Guangdong, China) 	<p>-Resource: Soehartati A. Gondho Wiardjo, Prof, PhD, Consultant Oncology Radiation (Jakarta)</p>
15.00 - 15.30	<p>TUTORIAL 6. THALASSEMIA SCREENING PROGRAM (B)</p> <p>Moderator: Panji Iriana Fianza, PhD, Internist, Consultant Hematology & Medical Oncology (Bandung)</p> <p>1. PREMARITAL SCREENING and THALASSEMIA GENETIC COUNSELLING: How do you make this program possible to conduct?</p> <p>Chen Ping, Prof (Nanning, Guanxi Medical University, Peoples Republic of China)</p> <p>2. RETROSPECTIVE/EXTENDED FAMILY MEMBERS SCREENING PROGRAM of TDT Patients and COMMUNITY THALASSEMIA SCREENING PROGRAM: Which is more recommended?</p> <p>Suthat Fucharoen, Prof, PhD, MD (Mahidol University, Bangkok)</p> <p>3. Q & A</p>	<p>ESMO PAGA 5: EARLY BREAST CANCER (eBC)</p> <p>1. IMPLEMENTATION of ESMO PAGA Guideline of eBC (15')</p> <p>Presenter: Hilman Tadjoedin, PhD, Internist, Consultant Hematology & Medical Oncology (Jakarta)</p> <p>2. Case Interactive Discussion: ? (15')</p> <p>-Resource: Bayu Brahma, Surgeon, Consultant Oncology (Jakarta)</p>
15.30 - 16.00	<p>TUTORIAL 7: THALASSEMIA SCREENING PROGRAM in INDONESIA</p> <p>Moderator 1: Tubagus Djumhana Atmakusuma, PhD, Internist, CHMo</p> <p>2. Iswari Setyaningsih, PhD, Pediatrics</p> <p>1. Thalassemia Retrospective Screening Program Extended Family Members of TDT Patients: Ministry of Health (MoH), RI in West Java and Central Java (2018 – 2021): Representative from the Directorate General of the Disease Prevention & Control (DIRJEN P2P) MoH, RI</p> <p>2. Thalassemia Premarital Testing in Jakarta Raya Province: Representative from MoH Office in Province of Jakarta Raya</p> <p>3. Panel Discussion:</p> <p>Panelists: 1. Suthat Fucharoen, Prof (Bangkok, Thailand)</p> <p>2. Chen Ping, Prof (Nanning, China)</p> <p>3. Chairman of YTI / POPTI</p>	<p>ESMO PAGA 6: METASTATIC BREAST CANCER (mBC)</p> <p>1. IMPLEMENTATION of ESMO PAGA Guideline of mBC (15')</p> <p>Presenter: Trinugroho Heri Fadjar, Internist, Consultant Hematology & Medical Oncology (Bandung)</p> <p>2. Case Interactive Discussion (15')</p> <p>-Resource: Ronald Alexander Hukom, MHSc, Internist, Consultant Hematology & Medical Oncology (Jakarta)</p>
16.00 - 16.30	<p>TUTORIAL 7: THALASSEMIA SCREENING PROGRAM in INDONESIA</p> <p>Moderator 1: Tubagus Djumhana Atmakusuma, PhD, Internist, CHMo</p> <p>2. Iswari Setyaningsih, PhD, Pediatrics</p> <p>1. Thalassemia Retrospective Screening Program Extended Family Members of TDT Patients: Ministry of Health (MoH), RI in West Java and Central Java (2018 – 2021): Representative from the Directorate General of the Disease Prevention & Control (DIRJEN P2P) MoH, RI</p> <p>2. Thalassemia Premarital Testing in Jakarta Raya Province: Representative from MoH Office in Province of Jakarta Raya</p> <p>3. Panel Discussion:</p> <p>Panelists: 1. Suthat Fucharoen, Prof (Bangkok, Thailand)</p> <p>2. Chen Ping, Prof (Nanning, China)</p> <p>3. Chairman of YTI / POPTI</p>	<p>ESMO PAGA 7: COLORECTAL CANCER (CRC)</p> <p>1. IMPLEMENTATION of ESMO PAGA Guideline of CRC (15')</p> <p>Presenter: Nadia Ayu Mulansari, Internist, Consultant Hematology & Medical Oncology (Jakarta)</p> <p>2. Case Interactive Discussion (15')</p> <p>-Resources: Ridho Ardhi Syaiful, Surgeon, Consultant Digestive Surgery (Jakarta)</p>
16.30 - 17.00	<p>TUTORIAL 7: THALASSEMIA SCREENING PROGRAM in INDONESIA</p> <p>Moderator 1: Tubagus Djumhana Atmakusuma, PhD, Internist, CHMo</p> <p>2. Iswari Setyaningsih, PhD, Pediatrics</p> <p>1. Thalassemia Retrospective Screening Program Extended Family Members of TDT Patients: Ministry of Health (MoH), RI in West Java and Central Java (2018 – 2021): Representative from the Directorate General of the Disease Prevention & Control (DIRJEN P2P) MoH, RI</p> <p>2. Thalassemia Premarital Testing in Jakarta Raya Province: Representative from MoH Office in Province of Jakarta Raya</p> <p>3. Panel Discussion:</p> <p>Panelists: 1. Suthat Fucharoen, Prof (Bangkok, Thailand)</p> <p>2. Chen Ping, Prof (Nanning, China)</p> <p>3. Chairman of YTI / POPTI</p>	<p>ESMO PAGA 8: GASTRIC CANCER</p> <p>1. IMPLEMENTATION of ESMO PAGA Guideline of Gastric Cancer (15')</p> <p>Presenter: Shinta Oktya Wardhani, PhD, Consultant Hematology & Medical Oncology (Malang)</p> <p>2. Case Interactive Discussion (15')</p>

	Outcome: Recommendation from the Experts and from the Parents of Transfusion Dependents Thalassemia Patients	Resource: Rabbinu Rangga Pribadi, Internist, Consultant Gastro-enterology (Jakarta)
17.00 - 17.15	COFFEE BREAK	
17.15 – 18.15	BREAK	
	BALL ROOM 1	
18.45 – 19.45	<p style="text-align: center;">DINNER SYMPOSIUM 1</p> <p style="text-align: center;">Moderator 1: Tbc Moderator 2: Tbc</p> <p style="text-align: center;">Speaker 1: Thalassemia Screening Program: Which the most effective & efficient screening system with minimal social impact of is highly recommended? Thalassemia International Federation (TIF) (online) (15') <i>Dr. Michael Angastionitis, Medical Advisor of TIF</i></p> <p style="text-align: center;">Speaker 2: Hemophilia Reimbursement System Worldwide: World Federation of Hemophilia (WFH) (Online) (15') <i>Cesar Garrido, President of WFH</i></p> <p style="text-align: center;">Panel Discussion (30') Panelists:</p> <ol style="list-style-type: none"> 1. Representative from Directorate General of the Disease Prevention & Control (DIRJEN P2P) MoH, RI 2. Representative from of the MoH Board of National Health Development Policy, MoH, RI 3. Representative from the Social Security Agency on Health Republic Indonesia (BPIS – Kesehatan) 	
19.45 – 22.45	The 6th SEAHEF (SOUTHEAST ASIA HEMATOLOGY NETWORK FORUM)	
	The Fourth (4th) SEATHAF (South East Asia Thalassemia Forum), the AFH (ASEAN FEDERATION of HEMATOLOGY) PANEL DISCUSSION	
19.45 – 21.25.	<p style="text-align: center;">SESSION 1. THALASSEMIA</p> <p style="text-align: center;">The National Health Insurance Reimbursement System in Prevention Program, Safe & Sufficient Donor Blood, Iron Chelating Agents and Iron Overload & Iron Toxicity: Learning from Our Neighboring Countries</p> <p style="text-align: center;">a. The Thalassemia Prevention Program (Thalassemia Screening Program: Retrospective/ Extended Family Members of TDT Patients Screening?, Premarital Screening?, Antenatal/Prenatal screening?, Community Screening?, Pre-implantation Genetic Diagnosis (PGD) ?</p> <p style="text-align: center;">b. Red Packed Cells (RPC) : NAT (Nucleic Acid Testing)?, Leukodepleted?, Coombs test?</p> <p style="text-align: center;">c. Iron Chelating Agents: Desferioxamine? Deferasirox? Deferiprone? Combination? Total Dose per Month?</p> <p style="text-align: center;">d. Iron Overload & Iron Toxicity: Surrogate markers for NTBI? The availability of MRIT2*? the use of Urine Iron Test to Monitor the efficacy of Deferiprone? Patient Compliance?</p>	
	<p style="text-align: center;">Moderator 1: Tubagus Djumhana Atmakusuma, PhD, Internist, Consultant Hematology & Medical Oncology</p> <p style="text-align: center;">Moderator 2: Pustika Amalia, Prof, PhD, Pediatrician, Consultant Hematology & Oncology</p> <p style="text-align: center;">Resources: Prof. Suthat & Prof. Chen Ping</p>	

19. 45 – 21.25	<p>Report of the 4 points above (in 6 slides at most) from each country of the Southeast Asia Region:</p> <ol style="list-style-type: none"> 1. Report from Cambodia Hematology Association / Expert (10') 2. Report from Laos Hematology Association / Expert (10')  3. Report from Malaysia Hematology Association / Expert (10') 4. Report from Myanmar Hematology Association / Expert (10') 5. Report from the Philippines Hematology Association / Expert (10') 6. Report from Singapore Hematology Association / Expert (10') 7. Report from Thailand Hematology Association / Expert (10') 8. Report from Vietnam Hematology Association / Expert (10') 9. Report from Indonesian Hematology Association / Expert (10')
	Comments from
21.25 – 22.15	<p style="text-align: center;">SESSION 2. HEMOPHILIA</p> <p>a. How is the National Health Insurance Regulations / Policy in Your Country for Coagulation Factor Concentrates, Immunosuppressive Agents, Plasmapheresis, Bypassing Agents and Humanized Bispecific Monoclonal Antibody Reimbursement System?</p> <p>b. How does your country cope with the National Hemophilia Costly Budget?</p>
	<p>Moderator 1: Bambang Sudarmanto, Pediatrician, Consultant Hematology & Oncology</p> <p>Moderator 2: Mika L Tobing, Internist, Consultant Hematology & Medical Oncology (Semarang)</p>
	<p>Report of the 2 points above (in 4 slides at most) from each country of the Southeast Asia Region:</p> <ol style="list-style-type: none"> 1. Report from the Cambodia Hematology Association / Expert (5') 2. Report from the Laos Hematology Association / Expert (5')  3. Report from the Malaysia Hematology Association / Expert (5') 4. Report from the Myanmar Hematology Association / Expert (5') 5. Report from the Philippines Hematology Association / Expert (5') 6. Report from the Singapore Hematology Association / Expert (5') 7. Report from the Thailand Hematology Association / Expert (5') 8. Report from the Vietnam Hematology Association / Expert (5') 9. Report from the Indonesian Hematology Association / Expert (5')
22.15 – 22.30	Q & A

	<p align="center">SESSION 4: The AFH (The ASEAN Federation of Hematology) PANEL DISCUSSION</p> <p align="center">Moderator 1: tbc Moderator 2: tbc</p>
22.30 – 23.00	<p align="center">SESSION 4: How is the future of the ASEAN FEDERATION of HEMATOLOGY (AFH)? What should we do to make the AFH sustainable?</p> <p align="center">Notes: the first AFH 2010 (in Malaysia, AFH 1), 2012 (in Singapore, AFH2), 2014 (in Thailand, AFH3), 2016 (In Philippines, AFH4), 2019 (instead of 2018, in Indonesia, AFH5), 2020 (AFH6, is supposed to be held in Myanmar. However, due to the COVID Pandemic (March 2020 until June 2023) and unstable situation in Myanmar, the Sixth AFH has not been held yet up to now:</p> <p align="center">b. Is there any specific solution to overcome this problem</p>
23.00	END OF DAY 1

B. SATURDAY, June 29th, 2024 (DAY 2)

Time	SATURDAY, June 29th 2024
07.00 – 07.45	REGISTRATION
	BALL ROOM 2
07.30 – 12.15	The First (1 st) ISHMO & ASCO JOINT SESSION (The Indonesian Society of Hematology & Medical Oncology and The American Society of Clinical Oncology)
07.30 – 07.45	Opening Speech from the ISHMO Opening Speech from the ASCO
07.45 – 08.45	SESSION 1 OF ASCO JOINT SESSION (Online) Topic: OVARIAN CANCER: Current ASCO Guideline Moderator: Tbc
	<p>a. Presentation of Current ASCO Guideline in Ovarian Cancer Speaker: ASCO Expert, Christina M. Annunziata, MD, PhD, FASCO (American cancer Society, Senior Vice President, Extramural Discovery Science) (Glenn Allen, VA, USA)</p> <p>b. Interactive Case Study (Polling) Presenter: ASCO?, Indonesian Expert?</p>
08.45 – 09.45	SESSION 2 OF ASCO JOINT SESSION (Online) Topic: BREAST CANCER: Current ASCO Guideline Moderator: TBC
	<p>a. Presentation of Current ASCO Guideline in Breast Cancer Speaker: Beverly Moy, MD, MPH (Massachusetts General Hospital, Boston, USA)</p> <p>b. Interactive Case Study (Polling) Presenter: ASCO?, Indonesian Expert?</p>
09.45 – 10.15	COFFEE BREAK and POSTER SESSION
10.15 - 11.15	SESSION 3 OF ASCO JOINT SESSION (Online) Topic: COLORECTAL CANCER: Current ASCO Guideline Moderator: TBC
	<p>a. Presentation of Current ASCO Guideline in Breast Cancer Speaker: Nancy Baxter, MD, PhD, FRCSC, FACS (University of Melbourne, Australia)</p>

	<p>b. Interactive Case Study (Polling) Presenter: ASCO?, Indonesian Expert?</p>	
11.15 – 12.15	<p>SESSION 4 OF ASCO JOINT SESSION (Offline) Topic: LUNG CANCER: Current ASCO Guideline Moderator: TBC</p>	
	<p>a. Presentation of Current ASCO Guideline in Breast Cancer Speaker: Matthew Gubens, MD, MS, FASCO (University of California, San Francisco, USA)</p> <p>b. Interactive Case Study (Polling) Presenter: ASCO?, Indonesian Expert?</p>	
12.15 – 13.15	<p>LUNCH SYMPOSIUM 2: Revolutionizing Care: Implementing Immunotherapy for First-Line Maintenance in Metastatic Urothelial Carcinoma (MERCK) Moderator: Aru Sudoyo, Prof, PhD, Internist, Consultant Hematology and Medical Oncology (Jakarta) Speaker 1: Overview of the evolving treatment landscape in mUC in Indonesia Nadia Ayumulansari, Internist, Consultant Hematology and Medical Oncology (Jakarta) Speaker 2 : Advance urothelial carcinoma treatment : Lesson from Avelumab clinical evidence and real practice (case) Dr. Dr. Yu-Chieh Tsai (Taiwan)</p>	
13.15 - 14.15	<p>LUNCH TIME AND POSTER SESSION</p>	
	<p>BALL ROOM 1</p>	<p>BALL ROOM 2</p>
14.15 - 15.15	<p>CORPORATE SYMPOSIUM 4 Topic: ? Moderator: ? Speaker 1: ? Speaker 2: ?</p>	<p>CORPORATE SYMPOSIUM 5 (COMBIPHAR) Topic: Moderator: Zubairi Djoerban, Prof, Consultant Hematology & Medical Oncology Speaker 1: Classification and Diagnosing of ITP Anna Mira Lubis. Internist, Consultant Hematology and Medical Oncology (Jakarta) Speaker 2: Pathophysiology and Management of ITP Lugyanti Suktisman, Internist, Consultant Hematology and Medical Oncology (Jakarta)</p>
15.15 - 16.15	<p>CORPORATE SYMPOSIUM 6 Topic: ? Moderator: ? Speaker 1: ? Speaker 2: ?</p>	<p>CORPORATE SYMPOSIUM 7 (KALBE) Topic: The Role of Edoxaban for the Treatment of Cancer associated Thromboembolism (VTE) Moderator: tbc Speaker 1: Budi Setiawan, PhD, Internist, Consultant Hematology & Medical Oncology (Semarang) Speaker 2: Lugyanti Sukrisman, PhD, Internist, Consulatnt Hematology & Medical Oncology</p>

16.15 - 17.15	TUTORIAL 8. PROS & CONTRAS based on CRITICAL APRAIALS PLASMAPHERESIS in IMMUNOLOGICAL & METABOLIC DISEASES, ORGAN FAILURE and in CANCERS: Efficacy and Safety Profiles compared to Ivlg and other medications ?	Tutorial 9. PROS & CONTRAS based on CRITICAL APRAIALS aPTT ? or aXa Factor ? to monitor the efficacy and safety of Unfractionated Heparin (UFH), Low molecular weight heparin (LMWH), Diract oral anticoagulants (DOAC) ?
17.15 – 18.15	BREAK	
	BALL ROOM 2	
18.15 - 19.45	DINNER SYMPOSIUM 2	
18.15 – 18.45	DINNER	
18.45 – 19.45	DINNER SYMPOSIUM 2 Topic: Tbc Moderator: Tbc Speaker 1: Tbc Speaker 2: ? (Option: 20 years Anniversary of the Indonesia – Singapore Medical Oncology Network (Online))	
19.45 – 22.45	SOUTHEAST ASIA NETWORK FORUM IN MEDICAL ONCOLOGY	
19.45 – 20.45	SESSION 1. The Fourteenth (14 th) SEAMOF (The South East Asia Medical Oncology Forum) Moderator 1: Ary Harryanto Reksodiputro , Prof, PhD, Internist, Hematology & Medical Oncology (Jakarta) Moderator 2: Nadia Ayumulansari, Internist, Hematology & Medical Oncology (Jakarta)	
	The Role of Medical Oncology in The Management of Cancer Patients: in MDT? In Daily Practice? Any obstacles/hurdles? How to Overcome this Problem?: Report from each country in the Southeast Asian Region a. Report from Malaysia Medical Oncologist Associations /Experts? (10') b. Report from Myanmar Medical Oncologist Associations /Experts? (10') c. Report from the Philippines Medical Oncologist Associations /Experts? (10') d. Report from Singapore Medical Oncologist Associations /Experts? (10') e. Report from Thailand Medical Oncologist Associations /Experts? (10') f. Report from Vietnam Medical Oncologist Associations /Experts? (10')	
20.45 - 21.45	SESSION 2 The First (1 st) SEAMOF and EAMO Network (The South East Indonesia Medical Forum and The East Asia Medical Oncology) Moderator 3: Tubagus Djumhana Atmakusuma (Indonesia) Moderator 4: Janice Tsang (Hong Kong)	
	The Role of Medical Oncology in The Management of Cancer Patients: in MDT? In Daily Practice? Any obstacles/hurdles? How to Overcome this Problem?: Report from each country in the Southeast Asian Region g. Report from Japan Medical Oncologist Associations /Experts ? (10') h. Report from South Korea Medical Oncologist Associations /Experts? (10')	

	<ul style="list-style-type: none"> i. Report from Taiwan Medical Oncologist Associations /Experts? (10') j. Report from Hong Kong Medical Oncologist Associations /Experts? (10') k. Report from Indonesia Medical Oncologist Associations /Experts? (10')
21.45 – 22.45	<p>SESSION 3. RECOMMENDATIONS from the SOUTHEAST and EAST ASIA MEDICAL ONCOLOGY EXPERTS NETWORK to the WHO with regards to the SOP based on ETHICAL CODE of the SYSTEMIC THERAPY in CANCER PATIENTS</p> <p>Moderator 1, 2, 3 & 4</p>
	Draft of the Recommendation: Vision, Missions, Objectives, Strategic Issues, SWOT analysis, Timeline, and PIC
22.45	END OF DAY 2

C. SUNDAY, June 30th, 2024 (DAY 3)

Time	SUNDAY, June 30 th , 2024
07.00 – 07.45	REGISTRATION
	BALL ROOM 2
07.30 – 08,45	The First (1 st) ISHMO and NCCN Network (The National Comprehensive Cancer Network)
07.30 – 07.45	INTRODUCTION: Opening Speech from the ISHMO (Indonesia) Opening Speech from the NCCN (USA)
07.45 – 08.45	ONLINE PRESENTATION OF NCCN: “How to Develop Sustainable and Living Guidelines in Cancer Treatment?” Moderator: ? Speaker: Wui-Jin Koh, MD
08.45 – 09.45	The First (1 st) INAGHMO Network (The Indonesian National Guidelines on Hematology and Medical Oncology) Moderator: ? Moderator: ?
08.45 – 08.55	b. Presentation of the National Guidelines of Leukemia including Application & Technical Guidance (ATG), Standard Operating Procedure (SOP) and Clinical Pathway (CP) Presenter: TBC
08.55 – 09.05	c. Presentation of Draft of Asian Guidelines of B Cell Non-Hodgkin Lymphoma, T-Cell Non-Hodgkin Lymphoma, Hodgkin Disease, Plasma Dyscrasia, Myeloma Multiple Presenter: TBC
09.05 – 09.15	d. Presentation of Draft of Guidelines Systemic and Supportive Therapy in Patient with Solid Tumor Cancer: Early Breast Cancer, Metastatic Breast Cancer, Cervical Cancer, Lung Cancer, Colorectal Cancer, Nasopharyngeal Cancer Presenter: TBC
09.15- 09.25	e. Presentation of Draft of National Standard Operating Procedures (SOPs) and Clinical Pathway of Bone Marrow Transplant (BMT) in Hodgkin Lymphoma, Myeloma Multiple, and Bone Marrow Failure Presenter: TBC
09.25 – 09.45	SPECIAL PRESENTATION The Role of the CARCINOMA MEHYLATION KIT METHOD of MOLECULAR TESTING in DETECTING CERVICAL, BLADDER, COLORECTAL and NASOPHAYNGEAL CANCERs Moderator; tbc Presenter: Joane, PhD (HYBRIBIO, Chaozhou, Guangdong, China)
09.45 – 10.15	COFFEE BREAK AND INTERACTIVE DISCUSSIONS IN EACH CORPORATE BOOTH

	BALL ROOM 1	BALL ROOM 2
10.00 - 0	<p align="center">CORPORATE SYMPOSIUM 8 (MSD)</p> <p>Theme: Immune Check Point Inhibitor for advanced-stage cancer: with a focus on Triple-Negative Breast Cancer (TNBC) and Non-Small Cell Lung Cancer (NSCLC)</p> <p>Moderator: A. Harryanto Reksodiputro, Prof, PhD, Internist, Consultant Hematology & Medical Oncology (Jakarta)</p> <p>Speaker 1: Applying Pembrolizumab pChemotherapy in the Neoadjuvant, followed by Adjuvant Pembrolizumab Post-Surgery as a Standard of Care for Early TNBC Andhika Rachman, PhD, Internist, Consultant Hematology & Medical Oncology (Jakarta)</p> <p>Speaker 2: Evidence-based medicine of Pembrolizumab and Chemotherapy in the management of mNSCLC patients, regardless of their PD-L1 status Ikhwan Rinaldi, Prof, PhD, PhD, MSc. MSc, Internist, Consultant Hematology & Medical Oncology (Jakarta) SpPD, KHOM, M.Epid)</p> <p align="center">Q & A</p>	<p align="center">CORPORATE SYMPOSIUM 9 (APL)</p> <p>Topic: Aiming for Better Outcomes in HR+ HER2- with CDK 4/6i+ & bone metastases management</p> <p>Moderator: Abdulmuthalib, Prof., Internist, Consultant Hematology & Medical Oncology (Jakarta)</p> <p>Speaker 1: Improving the Overall Survival in Endocrine-sensitive and Resistant Wulyo Rajabto, Internist, Consultant Hematology & Medical Oncology (Jakarta)</p> <p>Speaker 2: Consequences of Bone Metastases- A closer look at the impact of Skeletal-Related Events (SREs) Cosphiadi Irawan, PhD, Internist, Consultant Hematology & Medical Oncology (Jakarta)</p> <p align="center">Q & A</p>
11.00 – 12.00	<p align="center">CORPORATE SYMPOSIUM 10 (TAKEDA)</p> <p>Topic: A New Hope for Hodgkin Lymphoma Patients</p> <p>Moderator: Noorwati Sutandyo, Prof, PhD, Internist, Consultant Hematology & Medical Oncology (Jakarta)</p> <p>Speaker 1: Treatment Challenges and Recent Advances in the Management of Hodgkin Lymphoma: Focus on brentuximab vedotin Nadia Ayumulansari, Internist, Consultant Hematology & Medical Oncology (Jakarta)</p> <p>Speaker 2: Real-world Outcomes and case sharing experience in the Management of Hodgkin Lymphoma Johan Kurnianda, Internist, Consultant Hematology & Medical Oncology (Jakarta)</p> <p align="center">Q & A</p>	<p align="center">CORPORATE SYMPOSIUM 11 (ASTRA ZENECA)</p> <p>Topic: New Approach Treatment: Acalabrutinib Second Generation BTKi Update for Naive and R/R patient with/without High Risk Factor</p> <p>Moderator: Ikhwan Rinaldi, Prof, PhD, PhD. MSc. MSc, Internist, Consultant Hematology & Medical Oncology (Jakarta)</p> <p>Speaker 1: Acalabrutinib Pivotal Study for Naive and R/R CLL Djumhana Atmakusuma, PhD, MD, Internist, Consultant Hematology & Medical Oncology</p> <p>Speaker 2: Role of Clinical and Molecular Laboratory in CLL Updates on International Guideline and Building National Capacity Lyana Setiawan, PhD, Clinical Pathologists, Consultant Oncology (Jakarta)</p> <p align="center">Q & A</p>
12.00 - 13.00	LUNCH TIME & WINNER ANNOUNCEMENT OF POSTER COMPETITION	
	BALL ROOM 2	
13.00 – 15.15	NETWORK FORUM of the MEDICAL and the HEALTHCARE ASSOCIATIONS as well as with Others INSTITUTIONS	

13.00 – 14.00	SESSION 1. The First (1st) PERHOMPEDIN/ISHMO, PERDAFKI, HISFARSI, HIMPONI NETWORK FORUM: INTRODUCING & INAUGURATION of the CENTERS and UNITS of SYSTEMIC and SUPPORTIVE THERAPY in CANCER PATIENTS throughout INDONESIA and The SIGNING of Memorandum of Understanding (MoU),
14.00-14.15	SESSION 2. The First (1st) PERHOMPEDIN, PDSPA, PDSRI, PERDAFKI, HISFARSI, HIMPONI & BPJS-Kesehatan NETWORK FORUM: The SIGNING of MoU in DEVELOPING a TEAMWORK for Verifying, Monitoring, Evaluating and Auditing the USE of SYSTEMIC THERAPY in CANCER, as pilot project <u>TRASTUZUMAB</u> in eBC and mBC Patients by CHMO/ KHOM (Consultant Hematology & Medical Oncology) throughout Indonesia
14.15 – 14.30	SESSION 3. The First (1st) PHTDI/ISHTM, PPNI & IAI and BPJS Kesehatan NETWORK FORUM: The SIGNING of MoU in DEVELOPING & APPLYING of the PRACTICAL & TECHNICAL GUIDANCES in the MANAGEMENT of BLOOD DISEASES (Hemophilias, Thalassemias, Leukemias, Multiple Myeloma, Lymphomas, Bone Marrow Failure Syndrome, MPN) and BMT (Bone Marrow Transplant) throughout INDONESIA
14.30 – 14.45	SESSION 4. The First (1st) ALUMNI NETWORKING of CHMO & IFO of FMUI/CMGH/RSCM (Consultant Hematology & Medical Oncology and Internist Fellow Oncology): The SIGNING of MoU in DEVELOPING and ESTABLISHING the EDUCATION PROGRAM of HMO & INTERNATIONAL COMPETENCY CERTIFICATIONS
14.45 – 15.00	SESSION 5. The First (1st) DOARI in HOME of CNGH/RSCM NETWORKING (Dokter Asisten Riset Hematologi & Onkologi Medik): The SIGNING of MoU in DEVELOPING Education Training, Research and Publication Writing Program as well as Prevention Program (PIC ?)
15.00 – 15..15	SESSION 6. The First (1st) RESEARCH COLLABORATIVE PROGRAM between the ISHMO and ISHTM with INDUSTRIAL PHARMACY With HETERO, INOKEYS/KGBio/KALGENE/ KALBE
15.15 – 17.00	TENTATIVE PROGRAM: Tbc
17.00	CLOSING CEREMONY

	NEXT PROGRAM in 2024 and 2025
JULY & AUGUST 2024 and December 2024 & January 2025	POST the 9th ISMI HOTTI PROGRAM A. SUMMER CAMP BASIC HOME PROGRAM: JULY - AUGUST 2024 B. WINTER GAMES BASIC HOME PROGRAM: DECEMBER 2024 – JANUARY 2025
	SANHOTINDO, HOPHALAB and SANKORKOPINDO PROGRAM in collaboration with PERHOMPEDIN, PHTDI dan PTHI <ul style="list-style-type: none"> - SANHOTINDO = Yayasan Pengembangan Hematologi, Onkologi dan Transplantasi Indonesia - HOPHALAB = HOME PharmaLab → HOME (Hematologi & Onkologi Medik), Pharmacy and Laboratory <ul style="list-style-type: none"> - SANKORKOPINDO = Yayasan Koordinasi, Kolaborasi dan Kooperasi Indonesia - PERHOMPEDIN (Perhimpunan Hematologi & Onkologi Penyakit Dalam Indonesia) PHTDI (Perhimpunan Hematologi & Transfusi Darah Indonesia) PTHI (Perhimpunan Thrombosis Hemostatis Indonesia)
	Vision: As an OFFICIALY CERTIFIED and INTERNATIONALLY RECOGNIZED TRAINING INSTITUTE in HEMATOLOGY, ONCOLOGY, THROMBOSIS, TRANSPLANTATION and TRANSFUSION Mission: - To hold CERTIFIED Education Program, KNOWLEDGE and SKILL Trainings, Master & Doctoral Degree Objectives/ Goals: To update and upgrade the knowledge and skill of general practitioners, specialists and subspecialists related and collaborated with PERHOMPEDIN, PHTDI and PTHI as well as Nurses, Pharmacists and Public Strategic issues: 1. the 2023 Educational Standard (based on Competency Standard of Diagnosis and Management of Diseases and on Competency Standard of Procedures of Sub-specialization of Hematology & Medical Oncology from the Indonesian Medical Council (KKI), 2. the 2023 Indonesian National Laws in Health (Undang Undang Kesehatan No 17, 2023) Plan of Actions; Periodically Regular Training Program and Continuing Education Medical Program Time line: July and August → SUMMER CAMP BASIC HOME PROGRAM December and January → WINTER GAME BASIC HOME PROGRAM in Conjunction with
JULY & AUGUST 2024 and December 2024 & January 2025	POST the 9th (ninth) ISMI HOTTI PROGRAM C. SUMMER CAMP BASIC HOME PROGRAM: JULY - AUGUST 2024 D. WINTER GAMES BASIC HOME PROGRAM: DECEMBER 2024 – JANUARY 2025
	TOPICS:

	<p>See the “STANDARD PENDIDIKAN SUBSPELIALIS HEMATOLOGI & ONKOLOGI MEDIK” KKI Keputusan Konsil Kedokteran Indonesia Nomor 39/KKI/KEP/V/2023</p> <p>Standar Pendidikan Profesi Dokter Spesialis Penyakit Dalam Subspesialis Hematologi Onkologi Medik</p>
	<p>A. EDUCATION PROGRAM</p>
	<p>1. EDUCATION PROGRAM : CERTIFICATE of ATTANDENCE</p>
	<p>a. TUTORIALS, MASTER CLASS, INTERACTIVE DISCUSSION, CASE CONSULTATIVE with INTEGRATED PANELISTS , PUBLIC EDUCATION</p> <p>b. RESIDENTS of INTERNAL MEDICINE SELF ASSESSMENT (RIMSA)</p> <p>c. CERTIFICATES of KONWLEDGE: BASIC SCIENCE, DIAGNOSIS & MANAGEMENT, SURVEILLANCE, MASTER & DOCTORAL DEGREE</p> <p>d. CERTICATE of RESEARCH PROGRAM: IN VITRO, ANIMAL INVIVO/CLINICAL STUDIES, , CRITICAL APPRAISALS, PHARMACO-ECONO STUDIES. POST MARKETING SURVEILANCR & PHARMACOVIGILANCE, HEMOVIGILANCE, etc)</p>
	<p>2. TRAININGS: CERTIFICATES of COMPETENCIES /PROCEDURES: TECHNICAL DIAGNOSTIC PROCEDURES, EXPERRIESE in LABORATORY ASSESSMENT, THERAPEUTIC</p>
	<p>a. DRY WORK SHOPS, SHORT TRAININGS:</p>
	<p>a.1. GUIDELINES, PRACTICAL & TECHNICAL GUIDANCE, STANDARD OPERATING PROCEDURES (SOP), CLINICAL PATHWAYS (CP), CLINICAL AUDITS</p> <p>a. 2. WHITE PAPER of CLINICAL PRIVILEGE, CLINICAL PRIVILEGE DELINATION , STANDARDIZATION, ACCREDITATIONS</p> <p>a.3. BASIC SCIENCE in HEMATOLOGY, ONCOLOGY, THROMBOSIS-HEMOSTASIS, TRANSPLANTATION and TRANSFUSON</p> <p>a.4. GENETIC COUNSELIING In HEMOGLOBINOPATHY (THALASSEMIA and HEMOGLOBIN STRUTURAL VARIANTS) & in HEMOPHILIA and other HEREDITARY COAGULATIAN DISEASES (eg von Wilebrand diseasis</p> <p>a.5. GENETIC COUNSELING in CANCERS</p>
	<p>b. WET WORKSHOPS and PROCEDURAL TRAININGS:</p>
	<p>b,1, THERAPEUTIC PROCEDURES ;</p> <p>b.1.1. SYSTEMIC THERAPY in SOLID TUMOR (ONCOLOGY) and BLOOD CANCERS (HEMATOLOY CANCERS)</p> <p>b.1..2. SUPPORTIVE TREATMENTS in CANCERS (CANCER PAIN,</p> <p>b,1,3. APHERESIS: Therapeutic and Stem Cell HARVERSTING / COLLECTION</p> <p>b,1,4. PATIENT BLOOD MANAGEMEN (in Collaboration with Prof. James Isbister (Medical School, University of Sydney</p> <p>b,1,5, BONE MARROW TRANSPLANT (BMT) Autologous and Allogeneic</p> <p>b,1,6,ANTI THROMBOTIC AGENTS (Anticoagulants, antiplatelet agents, fibrinolytic agents)</p> <p>b,1,7, BLOOD TRANSFUSION and IRON CHELATING AGENTS in HEMOGLOBINOPATHY PATIENTS</p> <p>b,1,8, IMMUNOSUPPRSSIVE AGENTS</p>
	<p>b,2, DIAGNOSTIC SKILL PRPCEDURES</p> <p>b,2.1. Bone marrow biopsy and bone marrow aspiration</p> <p>b.2.2. Fine needle aspiration and core biopsy</p>

	b.2.3. Compression ultrasound for DVT (under supervision from Radiologist)
	b.3. DIAGNOSTIC LABORATORY PROCEDURES (in a team work with CLINICAL PATHOLOGISTS and ANATOMICAL PATHOLOGISTS)
	b.3,1, CYTOMORPHOLOGY of PERIPHERAL BLOOD SMEARS b.3,1, CYTOMORPHOLOGY of BONE MARROW ASPIRATES and BONE MARROW IMPRINT b.3.2. CYTOMORPHOLOGY of LYMPH NODE ASIRATES
	b.4. CAPABILITY to ASSESS the expertise results of LABORATORY TEST RESULTS
	b,4,1, Results of Complete Blood Count (CBC)Tests and peripheral blood smears b,,4,2, Results of Hemoglobin Electrpphoresis , DNA analysis of Hemoglobinopatht (Thalassmia and Hemoglobon Strctural Variants b.4.3. Results of Hemostasis, Blood Hemolytic Panel, Immunohematology b,4,4, Plasma electrophoresis, imminunofixation, free light chain, b.4.5. Results of cytomorphology of the bone marrow aspirates b.4.4. Results of histology of bone marrow biopsy b,4,6, Results of Immunocytochemistry (flowcytopemtry), immunohistochemisyry (IHC), tumor markers b,4,7, Results of RT-PCR, FISH, Sanger Sequensing, ONCOTYPE, MAMMOPRINT, Microsatelyte instability (MSI), Tumor mutation burden (TNB) b,4,8. Results of Next Generation Sequennsing (NGS): Whole genome sequencing, Comprehensive genome sequencing , etc
	b.5. CAPABILITY to ASSESS the expertise results of Radio-imaging RESULTS
	b.5.1. Results of Ultrasounds b.5.2. X rays, bone survey , spot photo b.5.4. CT scan, MRI, MRU T2* b.5.5. PET CT Scan, Bone scan